Answers are grounded in this paper and cite their sources.
Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor.
No takes yet. Share an insight, caveat, or question.
André et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: